Table 4.

Toxicity across dose quartiles

CharacteristicDose, × 106 CAR T cells per kgP 
0-1.3 n = 481.3-1.7 n = 461.7-2.4 n = 432.4-5.1 n = 43
Did patient develop CRS? 25 (52) 28 (61) 26 (60) 28 (65) .2 
Did patient experience neurotoxicity? 11 (23) 10 (22) 7 (16) 11 (26) >.9 
Unknown  
Grade ≥3 CRS 13 (27) 10 (22) 8 (19) 6 (14) .11 
Unknown  
Grade ≥3 neurotoxicity 2 (4.3) 4 (9.1) 1 (2.3) 4 (9.5) .6 
Unknown  
Treatment of neurotoxicity (choice, steroids [systemic])     .2 
Checked 2 (4.2) 3 (6.5) 1 (2.3) 6 (14)  
Unchecked 46 (96) 43 (93) 42 (98) 37 (86)  
Treatment of neurotoxicity (choice, IT steroids)      
Unchecked 48 (100) 46 (100) 43 (100) 43 (100)  
Treatment of neurotoxicity (choice, tocilizumab)     .6 
Checked 2 (4.2) 2 (4.3) 0 (0) 2 (4.7)  
Unchecked 46 (96) 44 (96) 43 (100) 41 (95)  
CharacteristicDose, × 106 CAR T cells per kgP 
0-1.3 n = 481.3-1.7 n = 461.7-2.4 n = 432.4-5.1 n = 43
Did patient develop CRS? 25 (52) 28 (61) 26 (60) 28 (65) .2 
Did patient experience neurotoxicity? 11 (23) 10 (22) 7 (16) 11 (26) >.9 
Unknown  
Grade ≥3 CRS 13 (27) 10 (22) 8 (19) 6 (14) .11 
Unknown  
Grade ≥3 neurotoxicity 2 (4.3) 4 (9.1) 1 (2.3) 4 (9.5) .6 
Unknown  
Treatment of neurotoxicity (choice, steroids [systemic])     .2 
Checked 2 (4.2) 3 (6.5) 1 (2.3) 6 (14)  
Unchecked 46 (96) 43 (93) 42 (98) 37 (86)  
Treatment of neurotoxicity (choice, IT steroids)      
Unchecked 48 (100) 46 (100) 43 (100) 43 (100)  
Treatment of neurotoxicity (choice, tocilizumab)     .6 
Checked 2 (4.2) 2 (4.3) 0 (0) 2 (4.7)  
Unchecked 46 (96) 44 (96) 43 (100) 41 (95)  

Data are given as n (%).

IT, intrathecal.

χ2 test of linear-by-linear association; Fisher exact test.

or Create an Account

Close Modal
Close Modal